Ameritas Investment Partners’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $70 | Hold |
64
| – | – | ﹤0.01% | 3171 |
|
|
2026
Q1 | $111 | Hold |
64
| – | – | ﹤0.01% | 3104 |
|
|
2025
Q4 | $111 | Hold |
64
| – | – | ﹤0.01% | 3125 |
|
|
2025
Q3 | $150 | Buy |
+64
| New | +$123 | ﹤0.01% | 3137 |
|
|
2025
Q2 | – | Sell |
-2,488
| Closed | -$4.05K | – | 3264 |
|
|
2025
Q1 | $4.05K | Hold |
2,488
| – | – | ﹤0.01% | 3013 |
|
|
2024
Q4 | $4.55K | Hold |
2,488
| – | – | ﹤0.01% | 3039 |
|
|
2024
Q3 | $14.4K | Hold |
2,488
| – | – | ﹤0.01% | 2793 |
|
|
2024
Q2 | $20.1K | Buy |
+2,488
| New | +$26.2K | ﹤0.01% | 2611 |
|
|
2023
Q2 | – | Sell |
-1,351
| Closed | -$13.3K | – | 3156 |
|
|
2023
Q1 | $13.3K | Hold |
1,351
| – | – | ﹤0.01% | 2618 |
|
|
2022
Q4 | $26.8K | Hold |
1,351
| – | – | ﹤0.01% | 2428 |
|
|
2022
Q3 | $27K | Hold |
1,351
| – | – | ﹤0.01% | 2365 |
|
|
2022
Q2 | $28K | Hold |
1,351
| – | – | ﹤0.01% | 2363 |
|
|
2022
Q1 | $58K | Hold |
1,351
| – | – | ﹤0.01% | 1971 |
|
|
2021
Q4 | $81K | Hold |
1,351
| – | – | ﹤0.01% | 1808 |
|
|
2021
Q3 | $116K | Hold |
1,351
| – | – | ﹤0.01% | 1594 |
|
|
2021
Q2 | $150K | Buy |
1,351
+96
| +8% | +$9.22K | 0.01% | 1459 |
|
|
2021
Q1 | $140K | Buy |
1,255
+130
| +12% | +$17.1K | 0.01% | 1446 |
|
|
2020
Q4 | $119K | Hold |
1,125
| – | – | 0.01% | 1473 |
|
|
2020
Q3 | $156K | Buy |
1,125
+54
| +5% | +$11.3K | 0.01% | 1169 |
|
|
2020
Q2 | $346K | Buy |
1,071
+383
| +56% | +$61.5K | 0.02% | 806 |
|
|
2020
Q1 | $61K | Buy |
688
+110
| +19% | +$6.78K | ﹤0.01% | 1546 |
|
|
2019
Q4 | $23K | Hold |
578
| – | – | ﹤0.01% | 2351 |
|
|
2019
Q3 | $14K | Hold |
578
| – | – | ﹤0.01% | 2576 |
|
|
2019
Q2 | $20K | Hold |
578
| – | – | ﹤0.01% | 2438 |
|
|
2019
Q1 | $26K | Hold |
578
| – | – | ﹤0.01% | 2248 |
|
|
2018
Q4 | $28K | Hold |
578
| – | – | ﹤0.01% | 2142 |
|
|
2018
Q3 | $39K | Hold |
578
| – | – | ﹤0.01% | 2128 |
|
|
2018
Q2 | $27K | Hold |
578
| – | – | ﹤0.01% | 2335 |
|
|
2018
Q1 | $33K | Hold |
578
| – | – | ﹤0.01% | 2153 |
|
|
2017
Q4 | $29K | Buy |
578
+129
| +29% | +$8K | ﹤0.01% | 2239 |
|
|
2017
Q3 | $32K | Hold |
449
| – | – | ﹤0.01% | 2154 |
|
|
2017
Q2 | $42K | Hold |
449
| – | – | ﹤0.01% | 2026 |
|
|
2017
Q1 | $36K | Buy |
+449
| New | +$35.8K | ﹤0.01% | 2050 |
|
Other funds holding INO
JT
BCM
ACM
EP
Ameritas Investment Partners's INO Position: Q2 2026 in Review
Ameritas Investment Partners held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 64 shares worth $70. The position accounts for ﹤0.01% of the portfolio, ranked #3171.
Ameritas Investment Partners first reported a position in INO in Q1 2017 and has held it in 33 quarters since. The position peaked at $346K in Q2 2020. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.
- Ameritas Investment Partners held 64 shares of Inovio Pharmaceuticals worth $70 as of Q2 2026.
- Ameritas Investment Partners left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
- Inovio Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #3171 holding.
- Ameritas Investment Partners first reported a position in Inovio Pharmaceuticals in Q1 2017 and has held it in 33 quarters since.
- Ameritas Investment Partners's Inovio Pharmaceuticals position peaked at $346K in Q2 2020.
- 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.
Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.